Filed pursuant to Rule 424(b)(3)
File No. 333-272286
PROSPECTUS SUPPLEMENT
(To Prospectus dated October 5, 2023, as supplemented
by the Prospectus Supplement dated November 15, 2023) |
|
January 30, 2024 |
Oxford Lane Capital Corp.
$750,000,000
Common Stock
This prospectus supplement contains
information which amends, supplements and modifies certain information contained in the prospectus dated October 5, 2023 (the “Base
Prospectus”) as supplemented by the prospectus supplement dated November 15, 2023 (together with this prospectus supplement and
the Base Prospectus, the “Prospectus”), which relate to the sale of shares of common stock of Oxford Lane Capital Corp. (the
“Company”) in an “at-the-market” offering pursuant to an Amended and Restated Equity Distribution Agreement dated
September 9, 2022, as amended pursuant to that certain Amendment No. 1 to the Amended and Restated Equity Distribution Agreement, dated
as of November 15, 2023, with Ladenburg Thalmann & Co. Inc. (the “Distribution Agent”). The Company’s investment
adviser, Oxford Lane Management, LLC, has agreed to pay to the Distribution Agent, if necessary, a supplemental payment per share that
will reflect the difference between the public offering price per share and the net proceeds per share received by the Company in this
offering such that the net proceeds per share received by the Company (before expenses) are not below the Company’s then current
net asset value per share.
You should carefully read the
entire Prospectus before investing in our common stock. You should also review the information set forth under the “Risk Factors”
section beginning on page 15 of the Base Prospectus and in our subsequent filings with the Securities and Exchange Commission that are
incorporated by reference into the Prospectus, before investing.
The terms “Oxford Lane,”
the “Company,” “we,” “us” and “our” generally refer to Oxford Lane Capital Corp.
PRIOR SALES PURSUANT TO THE “AT THE MARKET”
OFFERING
From November 15, 2023 to January
26, 2024, we sold a total of 10,932,563 shares of common stock pursuant to the “at-the-market” offering. The total amount
of capital raised as a result of these sales of common stock was approximately $53.7 million and net proceeds were approximately $53.1
million, after deducting the sales agent’s commissions and offering expenses.
THIRD QUARTER FINANCIAL HIGHLIGHTS AND RESULTS
| ● | On January 25, 2024, our Board of Directors declared the following distributions on our common stock:
|
Month Ending |
Record Date |
Payment Date |
Amount Per Share |
April 30, 2024 |
April 16, 2024 |
April 30, 2024 |
$0.08 |
May 31, 2024 |
May 17, 2024 |
May 31, 2024 |
$0.08 |
June 30, 2024 |
June 14, 2024 |
June 28, 2024 |
$0.08 |
| ● | Net asset value (“NAV”) per share as of December 31, 2023 stood at $4.82, compared with
a NAV per share on September 30, 2023 of $4.81. |
| ● | Net investment income (“NII”), calculated in accordance with U.S. generally accepted accounting
principles (“GAAP”), was approximately $48.7 million, or $0.23 per share, for the quarter ended December 31, 2023. |
| ● | Our core net investment income (“Core NII”) was approximately $82.7 million, or $0.39 per
share, for the quarter ended December 31, 2023. |
| o | Core NII incorporates all applicable cash distributions received, or entitled to be received (if any,
in either case), on our collateralized loan obligation (“CLO”) equity investments. See additional information under “Supplemental
Information Regarding Core Net Investment Income” below. |
| o | We emphasize that our taxable income may differ materially from our GAAP NII and/or our Core NII, and
that neither GAAP NII nor Core NII should be relied upon as indicators of our taxable income. |
| ● | Total investment income for the quarter ended December 31, 2023 amounted to approximately $79.2 million,
which represented an increase of approximately $4.8 million from the quarter ended September 30, 2023. |
| o | For the quarter ended December 31, 2023 we recorded investment income as follows: |
| ◾ | Approximately $73.6 million from our CLO equity and CLO warehouse investments, and |
| ◾ | Approximately $5.7 million from our CLO debt investments and other income. |
| ● | Our total expenses for the quarter ended December
31, 2023 were approximately $30.5 million, compared with total expenses of approximately $29.6 million for the quarter ended September
30, 2023. |
| ● | As of December 31, 2023, the following metrics applied (note that none of these metrics represented
a total return to shareholders): |
| o | The weighted average yield of our CLO debt investments at current cost was 16.6%, down from 18.5% as
of September 30, 2023. |
| o | The weighted average effective yield of our CLO equity investments at current cost was 16.5%, up from
16.3% as of September 30, 2023. |
| o | The weighted average cash distribution yield of our CLO equity investments at current cost was 24.0%,
down from 25.0% as of September 30, 2023. |
| ● | For the quarter ended December 31, 2023, we recorded a net increase in net assets resulting from operations
of approximately $52.4 million, or $0.25 per share, comprised of: |
| o | NII of approximately $48.7 million; |
| o | Net realized losses of approximately $3.1 million; and |
| o | Net unrealized appreciation of approximately $6.7 million. |
| ● | During the quarter ended December 31, 2023, we made additional investments of approximately $113.9 million,
and received approximately $30.2 million from sales and repayments of our CLO investments. |
| ● | For the quarter ended December 31, 2023, we issued a total of approximately 10.8 million shares of common
stock pursuant to an “at-the-market” offering. After deducting the sales agent’s commissions and offering expenses,
this resulted in net proceeds of approximately $52.2 million. As of December 31, 2023, we had approximately 219.6 million shares of common
stock outstanding. |
| ● | On January 25, 2024, our Board of Directors declared the required monthly dividends on our 6.75% Series
2024 Term Preferred Shares, 6.25% Series 2027 Term Preferred Shares, 6.00% Series 2029 Term Preferred Shares, and 7.125% Series 2029 Term
Preferred Shares as follows: |
Preferred
Shares Type |
Per Share
Dividend
Amount
Declared |
Record Dates |
Payment Dates |
6.75% - Series 2024 |
$ 0.14062500 |
March 15, 2024, April 16, 2024,
May 17, 2024 |
March 29, 2024, April 30, 2024,
May 31, 2024 |
6.25% - Series 2027 |
$ 0.13020833 |
March 15, 2024, April 16, 2024,
May 17, 2024 |
March 29, 2024, April 30, 2024,
May 31, 2024 |
6.00% - Series 2029 |
$ 0.12500000 |
March 15, 2024, April 16, 2024,
May 17, 2024 |
March 29, 2024, April 30, 2024,
May 31, 2024 |
7.125% - Series 2029 |
$ 0.14843750 |
March 15, 2024, April 16, 2024,
May 17, 2024 |
March 29, 2024, April 30, 2024,
May 31, 2024 |
In accordance with their terms, each of the 6.75% Series 2024 Term Preferred
Shares, 6.25% Series 2027 Term Preferred Shares, 6.00% Series 2029 Term Preferred Shares, and 7.125% Series 2029 Term Preferred Shares
will pay a monthly dividend at a fixed rate of 6.75%, 6.25%, 6.00% and 7.125%, respectively, of the $25.00 per share liquidation preference,
or $1.6875, $1.5625, $1.5000 and $1.78125 per share per year, respectively. This fixed annual dividend rate is subject to adjustment under
certain circumstances, but will not, in any case, be lower than 6.75%, 6.25%, 6.00% and 7.125% per year, respectively, for each of the
6.75% Series 2024 Term Preferred Shares, 6.25% Series 2027 Term Preferred Shares, 6.00% Series 2029 Term Preferred Shares and 7.125% Series
2029 Term Preferred Shares.
Supplemental Information Regarding Core Net Investment Income
We provide information relating to Core NII (a non-GAAP measure) on a supplemental
basis. This measure is not provided as a substitute for GAAP NII, but in addition to it. Our non-GAAP measures may differ from similar
measures by other companies, even in the event of similar terms being utilized to identify such measures. Core NII represents GAAP NII
adjusted for additional applicable cash distributions received, or entitled to be received (if any, in either case), on our CLO equity
investments. Oxford Lane’s management uses this information in its internal analysis of results and believes that this information
may be informative in assessing the quality of Oxford Lane’s financial performance, identifying trends in its results and providing
meaningful period-to-period comparisons.
Income from investments in the “equity” class securities of
CLO vehicles, for GAAP purposes, is recorded using the effective interest method; this is based on an effective yield to the expected
redemption utilizing estimated cash flows, at current cost, including those CLO equity investments that have not made their inaugural
distribution for the relevant period end. The result is an effective yield for the investment in which the respective investment’s
cost basis is adjusted quarterly based on the difference between the actual cash received, or distributions entitled to be received, and
the effective yield calculation. Accordingly, investment income recognized on CLO equity securities in the GAAP statement of operations
differs from the cash distributions actually received by the Company during the period (referred to below as “CLO equity adjustments”).
Furthermore, in order for the Company to continue qualifying as a regulated
investment company for tax purposes, we are required, among other things, to distribute at least 90% of our investment company taxable
income annually. While Core NII may provide a better indication of our estimated taxable income than GAAP NII during certain periods,
we can offer no assurance that will be the case, however, as the ultimate tax character of our earnings cannot be determined until after
tax returns are prepared at the close of a fiscal year. We note that this non-GAAP measure may not serve as a useful indicator of taxable
earnings, particularly during periods of market disruption and volatility, and, as such, our taxable income may differ materially from
our Core NII.
The following table provides a reconciliation of GAAP NII to Core
NII for the three months ended December 31, 2023:
| |
Three
Months Ended | |
| |
December 31, 2023 | |
| |
Amount | | |
Per Share
Amount | |
GAAP net investment income | |
$ | 48,731,802 | | |
$ | 0.23 | |
CLO equity adjustments | |
| 33,979,756 | | |
| 0.16 | |
Core net investment income | |
$ | 82,711,558 | | |
$ | 0.39 | |
false
424B3
0001495222
0001495222
2024-01-01
2024-01-30
0001495222
2023-12-31
2023-12-31
0001495222
2023-09-30
2023-09-30
iso4217:USD
xbrli:shares
xbrli:shares